Literature DB >> 25716856

Mouse model of OPRM1 (A118G) polymorphism increases sociability and dominance and confers resilience to social defeat.

Lisa A Briand1, Monica Hilario2, Holly C Dow3, Edward S Brodkin3, Julie A Blendy4, Olivier Berton3.   

Abstract

A single nucleotide polymorphism (SNP) in the human μ-opioid receptor gene (OPRM1 A118G) has been widely studied for its association in drug addiction, pain sensitivity, and, more recently, social behavior. The endogenous opioid system has been shown to regulate social distress and reward in a variety of animal models. However, mechanisms underlying the associations between the OPRM1 A118G SNP and these behaviors have not been clarified. We used a mouse model possessing the human equivalent nucleotide/amino acid substitution to study social affiliation and social defeat behaviors. In mice with the Oprm1 A112G SNP, we demonstrate that the G allele is associated with an increase in home-cage dominance and increased motivation for nonaggressive social interactions, similar to what is reported in human populations. When challenged by a resident aggressor, G-allele carriers expressed less submissive behavior and exhibited resilience to social defeat, demonstrated by a lack of subsequent social avoidance and reductions in anhedonia as measured by intracranial self-stimulation. Protection from social defeat in G-allele carriers was associated with a greater induction of c-fos in a resilience circuit comprising the nucleus accumbens and periaqueductal gray. These findings led us to test the role of endogenous opioids in the A112G mice. We demonstrate that the increase in social affiliation in G carriers is blocked by pretreatment with naloxone. Together, these data suggest a mechanism involving altered hedonic state and neural activation as well as altered endogenous opioid tone in the differential response to aversive and rewarding social stimuli in G-allele carriers.
Copyright © 2015 the authors 0270-6474/15/353582-09$15.00/0.

Entities:  

Keywords:  OPRM1 A118G; anhedonia; intracranial self-stimulation; social defeat; social interaction; μ-opioid

Mesh:

Substances:

Year:  2015        PMID: 25716856      PMCID: PMC4339361          DOI: 10.1523/JNEUROSCI.4685-14.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  50 in total

1.  Raphe GABAergic neurons mediate the acquisition of avoidance after social defeat.

Authors:  Collin Challis; Janette Boulden; Avin Veerakumar; Julie Espallergues; Fair M Vassoler; R Christopher Pierce; Sheryl G Beck; Olivier Berton
Journal:  J Neurosci       Date:  2013-08-28       Impact factor: 6.167

2.  DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses.

Authors:  Vincent Vialou; Alfred J Robison; Quincey C Laplant; Herbert E Covington; David M Dietz; Yoshinori N Ohnishi; Ezekiell Mouzon; Augustus J Rush; Emily L Watts; Deanna L Wallace; Sergio D Iñiguez; Yoko H Ohnishi; Michel A Steiner; Brandon L Warren; Vaishnav Krishnan; Carlos A Bolaños; Rachael L Neve; Subroto Ghose; Olivier Berton; Carol A Tamminga; Eric J Nestler
Journal:  Nat Neurosci       Date:  2010-05-16       Impact factor: 24.884

3.  Social stress in hamsters: defeat activates specific neurocircuits within the brain.

Authors:  S Kollack-Walker; S J Watson; H Akil
Journal:  J Neurosci       Date:  1997-11-15       Impact factor: 6.167

4.  Social conflict activates opioid analgesic and ingestive behaviors in male mice.

Authors:  G C Teskey; M Kavaliers; M Hirst
Journal:  Life Sci       Date:  1984-07-16       Impact factor: 5.037

5.  Opiate effects on social behavior of juvenile dogs as a function of social deprivation.

Authors:  P A Knowles; R L Conner; J Panksepp
Journal:  Pharmacol Biochem Behav       Date:  1989-07       Impact factor: 3.533

6.  Projections from the ventrolateral periaqueductal gray to endocrine regulatory subdivisions of the paraventricular nucleus of the hypothalamus in the rat.

Authors:  N S Floyd; K A Keay; C M Arias; P E Sawchenko; R Bandler
Journal:  Neurosci Lett       Date:  1996-12-13       Impact factor: 3.046

7.  Compensatory deficits following rejection: the role of social anxiety in disrupting affiliative behavior.

Authors:  Michael A Mallott; Jon K Maner; Nathan DeWall; Norman B Schmidt
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

8.  Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates.

Authors:  Christina S Barr; Melanie L Schwandt; Stephen G Lindell; J Dee Higley; Dario Maestripieri; David Goldman; Stephen J Suomi; Markus Heilig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-31       Impact factor: 11.205

9.  Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior.

Authors:  Stephen D Mague; Carolina Isiegas; Peng Huang; Lee-Yuan Liu-Chen; Caryn Lerman; Julie A Blendy
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-15       Impact factor: 11.205

10.  Response of the μ-opioid system to social rejection and acceptance.

Authors:  D T Hsu; B J Sanford; K K Meyers; T M Love; K E Hazlett; H Wang; L Ni; S J Walker; B J Mickey; S T Korycinski; R A Koeppe; J K Crocker; S A Langenecker; J-K Zubieta
Journal:  Mol Psychiatry       Date:  2013-08-20       Impact factor: 15.992

View more
  18 in total

1.  Synaptic Regulation by OPRM1 Variants in Reward Neurocircuitry.

Authors:  Dina Popova; Nidhi Desai; Julie A Blendy; Zhiping P Pang
Journal:  J Neurosci       Date:  2019-05-20       Impact factor: 6.167

2.  Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism.

Authors:  Nolan R Williams; Boris D Heifets; Brandon S Bentzley; Christine Blasey; Keith D Sudheimer; Jessica Hawkins; David M Lyons; Alan F Schatzberg
Journal:  Mol Psychiatry       Date:  2019-08-29       Impact factor: 15.992

Review 3.  Ketamine: The final frontier or another depressing end?

Authors:  Omar K Sial; Eric M Parise; Lyonna F Parise; Tamara Gnecco; Carlos A Bolaños-Guzmán
Journal:  Behav Brain Res       Date:  2020-02-01       Impact factor: 3.332

Review 4.  μ opioid receptor, social behaviour and autism spectrum disorder: reward matters.

Authors:  Lucie P Pellissier; Jorge Gandía; Thibaut Laboute; Jérôme A J Becker; Julie Le Merrer
Journal:  Br J Pharmacol       Date:  2017-05-04       Impact factor: 8.739

5.  Convergent Balancing Selection on the Mu-Opioid Receptor in Primates.

Authors:  Carolyn G Sweeney; Juliette M Rando; Helen N Panas; Gregory M Miller; Donna M Platt; Eric J Vallender
Journal:  Mol Biol Evol       Date:  2017-07-01       Impact factor: 16.240

6.  The µ-opioid system promotes visual attention to faces and eyes.

Authors:  Olga Chelnokova; Bruno Laeng; Guro Løseth; Marie Eikemo; Frode Willoch; Siri Leknes
Journal:  Soc Cogn Affect Neurosci       Date:  2016-08-16       Impact factor: 3.436

7.  Mouse model of OPRM1 (A118G) polymorphism has altered hippocampal function.

Authors:  Stephen D Mague; Russell G Port; Michael E McMullen; Greg C Carlson; Jill R Turner
Journal:  Neuropharmacology       Date:  2015-05-15       Impact factor: 5.250

Review 8.  Enkephalins: Endogenous Analgesics with an Emerging Role in Stress Resilience.

Authors:  Mathilde S Henry; Louis Gendron; Marie-Eve Tremblay; Guy Drolet
Journal:  Neural Plast       Date:  2017-07-11       Impact factor: 3.599

9.  Cell-type-specific role for nucleus accumbens neuroligin-2 in depression and stress susceptibility.

Authors:  Mitra Heshmati; Hossein Aleyasin; Caroline Menard; Daniel J Christoffel; Meghan E Flanigan; Madeline L Pfau; Georgia E Hodes; Ashley E Lepack; Lucy K Bicks; Aki Takahashi; Ramesh Chandra; Gustavo Turecki; Mary Kay Lobo; Ian Maze; Sam A Golden; Scott J Russo
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-16       Impact factor: 11.205

10.  μ-Opioid Receptor (Oprm1) Copy Number Influences Nucleus Accumbens Microcircuitry and Reciprocal Social Behaviors.

Authors:  Carlee Toddes; Emilia M Lefevre; Dieter D Brandner; Lauryn Zugschwert; Patrick E Rothwell
Journal:  J Neurosci       Date:  2021-07-22       Impact factor: 6.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.